Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.560
-0.050 (-3.11%)
At close: Oct 30, 2024, 4:00 PM
1.510
-0.050 (-3.21%)
Pre-market: Oct 31, 2024, 5:50 AM EDT
Regulus Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
30
Market Cap
102.13M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
So-Young International | 206.62M |
Agenus | 159.63M |
FONAR | 102.88M |
MDxHealth | 80.74M |
bluebird bio | 54.90M |
I-Mab | 3.49M |
RGLS News
- 22 days ago - Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 2 months ago - Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - PRNewsWire
- 2 months ago - Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - PRNewsWire
- 3 months ago - Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PRNewsWire
- 4 months ago - Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 5 months ago - Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes - PRNewsWire
- 5 months ago - Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - PRNewsWire
- 6 months ago - Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates - PRNewsWire